Industry Experts

Davy Ouyang is a seasoned biotech executive and scientific leader with over 20 years of experience in drug discovery and preclinical development across oncology, immuno-oncology, and autoimmune diseases. Davy serves as SVP of Innovation at Crown Bioscience following roles as Executive Vice President of R&D at Sidewinder Therapeutics and Vice President of Biology at InnoCare Pharma. Earlier in his career, Davy held research scientist positions at Merck & Co. and the Cancer Institute of New Jersey.

Dr. Ouyang has significant experience driving first-in-class ADC and biologics programs and a strong track record of advancing innovative drug candidates, including more than 20 IND-enabling molecules and 10 IND approvals across small molecules and biologics. Davy has extensive research experience, particularly in the areas of translational oncology, preclinical pharmacology, and platform development with a strong academic foundation and 44 peer-reviewed publications.

He received his PhD in Cancer Biology from the University of Hong Kong and completed postdoctoral training in oncology pharmacology with Dr. Cory Abate-Shen at Rutgers University.